Literature DB >> 18277567

[Intrathecal segmental analgesia with a single dose of bupivacaine for cancer pain in the abdominal wall].

Yuka Kurihara1, Junichi Ikegaki, Hiromi Kato, Suzuko Chigusa, Hiroshi Kaetsu.   

Abstract

A 48-year-old woman, diagnosed as colon cancer with metastases in the liver, lung, bone and left rectus abdominis, developed refractory left abdominal pain in spite of escalating administration of opioids and nerve block therapy, and intrathecal analgesia was applied. The tip of the catheter was intrathecally placed at the level of the T8 vertebra and pain relief was obtained with a daily dose of bupivacaine 36 mg producing segmental analgesia of the area between the 7th and 10th thoracic segments and preserving sensory and motor functions of the lower limbs. Face scale scores decreased from 5/6 to almost 0 after induction of the intrathecal analgesia. Side effects related to systemic opioids, such as nausea, vomiting and sleepiness, significantly improved and she was able to walk to the toilet. It is suggested that when the site of pain is limited to the truncus, intrathecal analgesia only with local anesthetics can be applied without affecting functions of the lower limbs.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18277567

Source DB:  PubMed          Journal:  Masui        ISSN: 0021-4892


  2 in total

1.  Bupivacaine administered intrathecally versus rectally in the management of intractable rectal cancer pain in palliative care.

Authors:  Iwona Zaporowska-Stachowiak; Grzegorz Kowalski; Jacek Luczak; Katarzyna Kosicka; Aleksandra Kotlinska-Lemieszek; Maciej Sopata; Franciszek Główka
Journal:  Onco Targets Ther       Date:  2014-10-06       Impact factor: 4.147

2.  Knockdown of lincRNA PADNA promotes bupivacaine-induced neurotoxicity by miR-194/FBXW7 axis.

Authors:  Fan Yuning; Chen Liang; Wang Tenghuan; Nan Zhenhua; Gong Shengkai
Journal:  Mol Med       Date:  2020-08-13       Impact factor: 6.354

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.